t’s been around since the 60’s, and it modulates the immune system by down-regulating Rnase L via cells’ toll-like receptors. Initial studies for Ampligen used very strict criteria and recruited only the most impaired patients from the top CFS physicians around the country – a group that typically doesn’t respond at all to any treatment>>Been around since the 60's...but never approved.Hence my problem with management. Carter's been running that company as his personal bank account for decades with nothing to show for it, but a bunch of diluted (and deluded?) shareholders.So, to sum:1) poorly-defined disease2) a "treatment" that's been around for (almost) ever with no real clinical record of success3) self-dealing managementsounds like a short to me, but it's only a buck stock so I'll just let it die.David
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra